TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27548766

Group type: EXPERIMENTAL
Intervention: Enalapril-folic acid (10 mg enalapril and 0.8 mg folic acid daily, n=7545)
Number of subjects: 15104

Group type: COMPARATOR
Intervention: Enalapril (10 mg daily, n=7559)
Number of subjects: 15104

Group type: EXPERIMENTAL
Intervention: Enalapril-folic acid among participants with CKD
Number of subjects: 15104

Group type: COMPARATOR
Intervention: Enalapril among participants with CKD
Number of subjects: 15104

Group type: EXPERIMENTAL
Intervention: Enalapril-folic acid among those without CKD
Number of subjects: 15104
Study: 25335675

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (20 g per day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (enteral formula without arginine)
Number of subjects: 82
Study: 23736156

Group type: EXPERIMENTAL
Intervention: Structured education pulmonary rehabilitation programme
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study: 20492851

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) at 10 mg for 1 week and then 20 mg for 1 week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo transdermal system (PTS)
Number of subjects: 30
Study: 19057626

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic (lidocaine 0.5%)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid
Number of subjects: 72
Study: 16643445

Group type: EXPERIMENTAL
Intervention: Intensive therapy (including autologous stem cell transplantation) for patients <60 years
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Intensive therapy (including autologous stem cell transplantation) for patients aged 60-64 years
Number of subjects: 452

Group type: COMPARATOR
Intervention: Historic control group (conventionally treated patients) for patients <60 years
Number of subjects: 452

Group type: COMPARATOR
Intervention: Historic control group (conventionally treated patients) for patients aged 60-64 years
Number of subjects: 452
Study: 12794815

Group type: EXPERIMENTAL
Intervention: Etanercept plus methotrexate
Number of subjects: 79
Study: 10831180

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 47
Study: 8772604

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU daily for 5 days/week) plus 1000 mg calcium daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Calcium alone (1000 mg daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 1630044

Group type: EXPERIMENTAL
Intervention: Regular beta-agonist inhalation
Number of subjects: 20

Group type: COMPARATOR
Intervention: As required beta-agonist inhalation
Number of subjects: 20
Study: 6481113

Group type: EXPERIMENTAL
Intervention: Histologic gastritis in GER patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Severe gastritis (grades 2 or 3) in GER patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Grades 0 or 1 gastritis in GER patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 23
Study: 31592623

Group type: EXPERIMENTAL
Intervention: 3 g/kg of CHO beverage
Number of subjects: 10

Group type: COMPARATOR
Intervention: Noncaloric PLA
Number of subjects: 10
Study: 29076967

Group type: EXPERIMENTAL
Intervention: Supervised mock codes with debriefing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Just-in-time training with a peer
Number of subjects: 0
Study: 25788018

Group type: EXPERIMENTAL
Intervention: Education programme on harmful effects of salt and how to reduce salt intake delivered to children for one school term (about 3.5 months).
Number of subjects: 832

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 832
Study: 23142014

Group type: EXPERIMENTAL
Intervention: Neurodynamic sliding intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 28
Study: 21568985

Group type: EXPERIMENTAL
Intervention: Intra-plexus blocks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Peri-plexus blocks
Number of subjects: 170
Study: 19305279

Group type: EXPERIMENTAL
Intervention: LOP group (mean cuff pressure 151 mm Hg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (mean cuff pressure 300 mm Hg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hypothetical control data (250 mm Hg)
Number of subjects: 21
Study: 16766544

Group type: EXPERIMENTAL
Intervention: Isoflavone-containing soy-based nutritional supplements for 8 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Isoflavone-free milk protein for 8 weeks (Control group)
Number of subjects: 32
Study: 15616415

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 1181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1181
Study: 11422000

Group type: EXPERIMENTAL
Intervention: Anastrozole (7 mg loading dose on day 1, followed by 1 mg daily on days 2-11)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9289406

Group type: EXPERIMENTAL
Intervention: Turner syndrome patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 8281831

Group type: EXPERIMENTAL
Intervention: Immediate physiotherapy without immobilisation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Plaster immobilisation for six weeks
Number of subjects: 41
Study: 3573541

Group type: EXPERIMENTAL
Intervention: L-triiodothyronine (T3) treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sodium ipodate treatment
Number of subjects: 14
Study: 29979940

Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training (RMT) in addition to regular chest physiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular chest physiotherapy (Control Group)
Number of subjects: 40
Study: 30939911

Group type: EXPERIMENTAL
Intervention: Low thermal damage device
Number of subjects: 75

Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 75
Study: 28724041

Group type: EXPERIMENTAL
Intervention: Rhubarb (30.0 g/d) for 7 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional therapy for 7 days
Number of subjects: 80
Study: 25542311

Group type: EXPERIMENTAL
Intervention: ABVE‐PC + 21 Gy involved field radiation therapy (IFRT)
Number of subjects: 1712

Group type: COMPARATOR
Intervention: ABVE‐PC
Number of subjects: 1712

Group type: EXPERIMENTAL
Intervention: ABVE‐PC + 21 Gy IFRT
Number of subjects: 1712
Study: 23680435

Group type: EXPERIMENTAL
Intervention: Escitalopram (dose range around 10-15 mg/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 21542939

Group type: EXPERIMENTAL
Intervention: Training township hospital midwives and instructing them in how to provide systematic maternal care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informing women in the community of the importance of prenatal care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Providing basic medical instruments to the hospitals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 19931828

Group type: EXPERIMENTAL
Intervention: Telephone Support Services (TSS)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Enhanced Usual Care (UC+)
Number of subjects: 179
Study: 17004666

Group type: EXPERIMENTAL
Intervention: Warmed cotton blankets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-controlled warming gowns
Number of subjects: 0
Study: 15080852

Group type: EXPERIMENTAL
Intervention: Patient-controlled on-demand treatment with esomeprazole, 20 mg daily
Number of subjects: 1357

Group type: COMPARATOR
Intervention: General practitioner-controlled intermittent treatment with esomeprazole, 40 mg daily for 2 weeks
Number of subjects: 1357

Group type: COMPARATOR
Intervention: General practitioner-controlled intermittent treatment with esomeprazole, 40 mg daily for 4 weeks
Number of subjects: 1357
Study: 12160097

Group type: EXPERIMENTAL
Intervention: Abstainers
Number of subjects: 187

Group type: COMPARATOR
Intervention: Drinkers
Number of subjects: 187
Study: 9691834

Group type: EXPERIMENTAL
Intervention: Randomized patients
Number of subjects: 164

Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 164
Study: 7640140

Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.1 micrograms min-1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Doppler sonography
Number of subjects: 19
Study: 2475323

Group type: EXPERIMENTAL
Intervention: Opioid meperidine (150 mg, p.o.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Antidepressant imipramine (100 mg, p.o.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 780063

Group type: EXPERIMENTAL
Intervention: 80 mg oxprenolol daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: 4 mg diazepam daily
Number of subjects: 32
Study: 30759132

Group type: EXPERIMENTAL
Intervention: Vi-DT vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vi-PS vaccine
Number of subjects: 100
Study: 27161285

Group type: EXPERIMENTAL
Intervention: Formulations containing Cichorium intybus root extract with UV filters
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Formulations containing Cichorium intybus root extract without UV filters
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vehicle formulations containing UV filters
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vehicle formulations without UV filters
Number of subjects: 50
Study: 25626920

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (1 mg/mL) for three consecutive months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (10 mg/mL) for three consecutive months
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (1 mg/mL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (10 mg/mL)
Number of subjects: 26
Study: 23298693

Group type: EXPERIMENTAL
Intervention: Interactive music intervention
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Passive music intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: No-music control
Number of subjects: 39
Study: 21546927

Group type: EXPERIMENTAL
Intervention: Normal protein breakfast (NP; 18 ± 1 g protein)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Higher protein breakfast (HP; 50 ± 1 g protein)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Breakfast consumption (both NP and HP)
Number of subjects: 10
Study: 20396724

Group type: EXPERIMENTAL
Intervention: Poetam and anaferon (pediatric formulation) administered in combination with iron preparation
Number of subjects: 0
Study: 17520399

Group type: EXPERIMENTAL
Intervention: Epidural ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous ondansetron
Number of subjects: 0
Study: 15506584

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 226

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 226
Study: 11451697

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg orally once daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg orally once daily
Number of subjects: 410
Study: 10052247

Group type: EXPERIMENTAL
Intervention: Etoposide 80 mg/m2 day 1-3, folinic acid 100 mg/m2 day 1-3, 5-fluorouracil 340 mg/m2 day 1-3, and epirubicin 60 mg/m2 day 1, repeated every three weeks
Number of subjects: 23
Study: 7746030

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 30646302

Group type: EXPERIMENTAL
Intervention: Smoked cannabis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaporized cannabis
Number of subjects: 0
Study: 26857383

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring with health coaching telephone calls and telemonitoring.
Number of subjects: 1437

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1437
Study: 24444280

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus desmopressin (0.3 μg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ticagrelor alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus desmopressin
Number of subjects: 21
Study: 22776554

Group type: EXPERIMENTAL
Intervention: Tailored Internet and mobile phone based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (standard cardiac rehabilitation without tailored intervention)
Number of subjects: 0
Study: 20510459

Group type: EXPERIMENTAL
Intervention: venlafaxine ER
Number of subjects: 258

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 258
Study: 18789008

Group type: EXPERIMENTAL
Intervention: ronkoleukin
Number of subjects: 33
Study: 17274312

Group type: EXPERIMENTAL
Intervention: HBO2 treatment at 2.2 bar
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: HBO2 treatment at 2.5 bar
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: HBO2 treatment (both protocols)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: HBO2 treatment with positive expectation
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: HBO2 treatment with indifferent expectation
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: HBO2 treatment with negative expectation
Number of subjects: 360
Study: 12599053

Group type: EXPERIMENTAL
Intervention: Rhesus monkey rotavirus-based quadrivalent vaccine (4 x 10^5 plaque-forming units/dose)
Number of subjects: 2207

Group type: EXPERIMENTAL
Intervention: Rhesus monkey rotavirus-based quadrivalent vaccine
Number of subjects: 2207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2207
Study: 10731460

Group type: EXPERIMENTAL
Intervention: Immediate intervention condition (High 5 project)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Delayed intervention control condition
Number of subjects: 28
Study: 8841152

Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan 1 hour before 50 mg quinidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: 50 mg quinidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan (poor metabolizers)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan (extensive metabolizers with quinidine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan (extensive metabolizers)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Capsaicin-induced cough frequency
Number of subjects: 12
Study: 1738578

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation with naloxone (0.4 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vibratory stimulation with placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 21
Study: 6732565

Group type: EXPERIMENTAL
Intervention: Anterior trabeculoplasty (ATM)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Posterior trabeculoplasty (PTM)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both anterior and posterior trabeculoplasty
Number of subjects: 118
Study: 31103881

Group type: EXPERIMENTAL
Intervention: Psychosocial adversity risk
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Hair cortisol
Number of subjects: 297

Group type: COMPARATOR
Intervention: Sociodemographic adversity risk
Number of subjects: 297
Study: 30412448

Group type: EXPERIMENTAL
Intervention: Abicipar 1 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Abicipar 2 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg
Number of subjects: 64
Study: 27655761

Group type: EXPERIMENTAL
Intervention: High-fat meal (HFM) - 250 mL (520 kcal) consisting of rapeseed oil (440 kcal), emulsifier, sucrose, flavor cocktail
Number of subjects: 17

Group type: COMPARATOR
Intervention: Water load (WL)
Number of subjects: 17
Study: 23765873

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 4 or 8 mg/kg
Number of subjects: 102
Study: 22443478

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 358
Study: 20736125

Group type: EXPERIMENTAL
Intervention: Feeding 1 hour before examination (arm 1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Feeding schedule adjusted to ensure no feeding within 2 hours before examination (arm 2)
Number of subjects: 34
Study: 18509177

Group type: EXPERIMENTAL
Intervention: Taxanes in the metastatic setting
Number of subjects: 982
Study: 15950838

Group type: EXPERIMENTAL
Intervention: Text + pictogram labels (experimental group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Text-only labels (control group)
Number of subjects: 87
Study: 12576914

Group type: EXPERIMENTAL
Intervention: Long-term exercise program (18 months)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Short-term exercise program (3 months)
Number of subjects: 140
Study: 11783207

Group type: EXPERIMENTAL
Intervention: CHM plus chemotherapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Single chemotherapy
Number of subjects: 86
Study: 8606329

Group type: EXPERIMENTAL
Intervention: DES-exposed individuals (253 sons and 296 daughters)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Unexposed individuals (241 men and 246 women)
Number of subjects: 549
Study: 1768539

Group type: EXPERIMENTAL
Intervention: Low-dose adrenaline infusions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenylephrine infusions
Number of subjects: 30
Study: 7034858

Group type: EXPERIMENTAL
Intervention: Povidone-iodine pessaries for two weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Povidone-iodine pessaries
Number of subjects: 100
Study: 29858149

Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg) plus Albendazole (400 mg)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Albendazole (400 mg) plus Oxantel Pamoate (25 mg/kg)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg) plus Tribendimidine (200 mg or 400 mg)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg) alone
Number of subjects: 701
Study: 27625133

Group type: EXPERIMENTAL
Intervention: Core needle biopsy (Group A)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Fine needle aspiration cytology (Group B)
Number of subjects: 105
Study: 25734218

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 0
Study: 22817789

Group type: EXPERIMENTAL
Intervention: Inspection during instrument insertion (3 minutes during insertion + 6 minutes during withdrawal)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inspection during instrument withdrawal (9 minutes)
Number of subjects: 100
Study: 20946233

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets with slow-release insecticides (KO Tab 123)
Number of subjects: 15254
Study: 18179321

Group type: EXPERIMENTAL
Intervention: Individuating or personalizing experience with an outgroup member
Number of subjects: 0
Study: 16009169

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice a week for 5 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 40
Study: 12890954

Group type: EXPERIMENTAL
Intervention: Periprostatic local anesthesia with 1% lidocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 50
Study: 10873672

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (400 mg/day for 5 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (10 and 15 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin C supplementation (15 weeks) followed by placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Withdrawal from vitamin C supplementation
Number of subjects: 0
Study: 9168289

Group type: COMPARATOR
Intervention: Methylprednisolone for 24 hours
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Methylprednisolone for 48 hours
Number of subjects: 499

Group type: COMPARATOR
Intervention: Tirilazad for 48 hours
Number of subjects: 499
Study: 7680374

Group type: EXPERIMENTAL
Intervention: Pamidronate (high dose 600 mg/d and low dose 300 mg/d)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Pamidronate (low dose 300 mg/d)
Number of subjects: 161
Study: 3524742

Group type: EXPERIMENTAL
Intervention: Loop ileostomy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Loop transverse colostomy
Number of subjects: 47
Study: 30225981

Group type: EXPERIMENTAL
Intervention: Internet-based weight loss intervention for mothers
Number of subjects: 371

Group type: COMPARATOR
Intervention: Standard Women, Infants, Children (control)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 371
Study: 29905927

Group type: EXPERIMENTAL
Intervention: regorafenib-FOLFIRI
Number of subjects: 181

Group type: COMPARATOR
Intervention: placebo-FOLFIRI
Number of subjects: 181
Study: 27318866

Group type: EXPERIMENTAL
Intervention: Dual low-density lipoprotein cholesterol-lowering therapy (DLLT) with statin-ezetimibe combination
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DLLT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 100
Study: 24004695

Group type: EXPERIMENTAL
Intervention: Ventral attention network modulation by task-irrelevant memory signals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bottom-up, stimulus-driven distraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top-down control of attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in connectivity among critical nodes of ventral and dorsal frontoparietal regions
Number of subjects: 0